|
1
|
Sampson VB, Yoo S, Kumar A, Vetter NS and
Kolb EA: MicroRNAs and potential targets in osteosarcoma: Review.
Front Pediatr. 3:692015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lim HJ and Yang JL: Regulatory roles and
therapeutic potential of microRNA in sarcoma. Crit Rev Oncol
Hematol. 97:118–130. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Varshney J and Subramanian S: MicroRNAs as
potential target in human bone and soft tissue sarcoma
therapeutics. Front Mol Biosci. 2:312015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou G, Shi X, Zhang J, Wu S and Zhao J:
MicroRNAs in osteosarcoma: From biological players to clinical
contributors, a review. J Int Med Res. 41:1–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou W, Hao M, Du X, Chen K, Wang G and
Yang J: Advances in targeted therapy for osteosarcoma. Discov Med.
17:301–307. 2014.PubMed/NCBI
|
|
6
|
Zhang J, Yan YG, Wang C, Zhang SJ, Yu XH
and Wang WJ: MicroRNAs in osteosarcoma. Clin Chim Acta. 444:9–17.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang LQ, Sun SL, Li WY, Feng Z, Xu XY,
Zhuang QS and Fang J: Decreased expression of tumor suppressive
miR-874 and its clinical significance in human osteosarcoma. Genet
Mol Res. 14:18315–18324. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhou S, Wang B, Hu J, Zhou Y, Jiang M, Wu
M, Qin L and Yang X: miR-421 is a diagnostic and prognostic marker
in patients with osteosarcoma. Tumour Biol. Jan 13–2016.(Epub ahead
of print).
|
|
9
|
Niu G, Li B, Sun L and An C: MicroRNA-153
inhibits osteosarcoma cells proliferation and invasion by targeting
TGF-β2. PLoS One. 10:e01192252015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang J, Yang Y, Yang T, Yuan S, Wang R,
Pan Z, Yang Y, Huang G, Gu F, Jiang B, et al: Double-negative
feedback loop between microRNA-422a and forkhead box (FOX)G1/Q1/E1
regulates hepatocellular carcinoma tumor growth and metastasis.
Hepatology. 61:561–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gougelet A, Pissaloux D, Besse A, Perez J,
Duc A, Dutour A, Blay JY and Alberti L: Micro-RNA profiles in
osteosarcoma as a predictive tool for ifosfamide response. Int J
Cancer. 129:680–690. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bahador R, Taheriazam A, Mirghasemi A,
Torkaman A, Shakeri M, Yahaghi E and Goudarzi PK: Tissue expression
levels of miR-29b and miR-422a in children, adolescents, and young
adults' age groups and their association with prediction of poor
prognosis in human osteosarcoma. Tumour Biol. 37:3091–3095. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Faltejskova P, Svoboda M, Srutova K,
Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K,
Kiss I, et al: Identification and functional screening of microRNAs
highly deregulated in colorectal cancer. J Cell Mol Med.
16:2655–2666. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang L, Liu M, Zhu H, Rong W, Wu F, An S,
Liu F, Feng L, Wu J and Xu N: Identification of recurrence-related
serum microRNAs in hepatocellular carcinoma following hepatectomy.
Cancer Biol Ther. 16:1445–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin YZ, Xie XC, Liu HZ, Lai H, Qiu H and
Ge LY: Screening and preliminary validation of miRNAs with the
regulation of hTERT in colorectal cancer. Oncol Rep. 33:2728–2736.
2015.PubMed/NCBI
|
|
16
|
Zheng G, Du L, Yang X, Zhang X, Wang L,
Yang Y, Li J and Wang C: Serum microRNA panel as biomarkers for
early diagnosis of colorectal adenocarcinoma. Br J Cancer.
111:1985–1992. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang S, Chen L, Huang H and Zhi D: The
experimental study of miRNA in pituitary adenomas. Turk Neurosurg.
23:721–727. 2013.PubMed/NCBI
|
|
18
|
Won KY, Kim YW and Park YK: Expression of
Smad and its signalling cascade in osteosarcoma. Pathology.
42:242–247. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Johnsen SA, Subramaniam M, Janknecht R and
Spelsberg TC: TGFbeta inducible early gene enhances
TGFbeta/Smad-dependent transcriptional responses. Oncogene.
21:5783–5790. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zaidi SK, Sullivan AJ, van Wijnen AJ,
Stein JL, Stein GS and Lian JB: Integration of Runx and Smad
regulatory signals at transcriptionally active subnuclear sites.
Proc Natl Acad Sci USA. 99:8048–8053. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nikitovic D, Zafiropoulos A, Katonis P,
Tsatsakis A, Theocharis AD, Karamanos NK and Tzanakakis GN:
Transforming growth factor-beta as a key molecule triggering the
expression of versican isoforms v0 and v1, hyaluronan synthase-2
and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB
Life. 58:47–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nikitovic D, Chalkiadaki G, Berdiaki A,
Aggelidakis J, Katonis P, Karamanos NK and Tzanakakis GN: Lumican
regulates osteosarcoma cell adhesion by modulating TGFβ2 activity.
Int J Biochem Cell Biol. 43:928–935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ren XF, Mu LP, Jiang YS, Wang L and Ma JF:
LY2109761 inhibits metastasis and enhances chemosensitivity in
osteosarcoma MG-63 cells. Eur Rev Med Pharmacol Sci. 19:1182–1190.
2015.PubMed/NCBI
|
|
24
|
Xu S, Yang S, Sun G, Huang W and Zhang Y:
Transforming growth factor-beta polymorphisms and serum level in
the development of osteosarcoma. DNA Cell Biol. 33:802–806. 2014.
View Article : Google Scholar : PubMed/NCBI
|
